Michael Szlamkowicz

Michael Szlamkowicz

Partner, New York

Michael Szlamkowicz takes a business-oriented approach to his work, helping his clients anticipate and solve a wide range of commercial and legal challenges.

Michael focuses his practice on complex corporate and transactional matters and primarily represents private equity and pension fund sponsors and their portfolio companies, especially in connection with leveraged acquisitions, divestitures, joint ventures, minority investments, financings, restructurings, and general corporate matters.

He also has comprehensive experience with both international and domestic transactions, and frequently counsels on a variety of securities law, corporate governance, and strategic matters. His industry experience includes life sciences, energy, media, fashion and branding, entertainment, telecommunications, information technology, retail, automotive, chemical, and financial services.

Michael studied at McGill University and the Université de Montréal.

Awards and recognitions

2018

Healthcare: Life Sciences
Legal 500 US

Education and admissions

Education

Bachelor of Commerce (Finance, Marketing), McGill University

Bachelor of Laws, University of Montreal

J.D., University of Montreal

Bar admissions and qualifications

New York

Quebec

Representative experience

21st Century Fox in its joint venture with Apollo to create a leading global multi-platform content provider, bringing together Endemol and Shine Group.

Actis on its sale of Anthelio Healthcare Solutions to Atos.

Alcon in the acquisition of Transcend Medical, Inc., developer of technologies for the treatment of glaucoma.

Ford on its acquisition of SAIPS, an Israel-based machine learning company.

Google in its acquisition of Lift Labs.

Next Issue Media in connection with a US$50m investment by KKR.

Novartis in its acquisition of Encore Vision, focused on the development of a novel treatment in presbyopia.

Novartis in its US$665m acquisition of Selexys Pharmaceuticals, a developer of therapeutics to treat pain associated with blood/inflammatory disorders like sickle cell disease.

One Rock Capital on its acquisition of Chevron's Hawaii assets.

One Rock Capital on its acquisition of FXI, a leading foam producer.

Pamplona Capital in its acquisition of BBB Industries.

Pamplona Capital in its acquisition of Charter Nex Holdings.

Pfizer on its immuno-oncology research collaboration with Western Oncolytics to investigate novel oncolytic virus technology.

Valeant on the sale of Dendreon Pharmaceuticals, Inc. to the Sanpower Group Co., Ltd for US$820m.

*Matter handled prior to joining Hogan Lovells.

Latest thinking and events

Hogan Lovells Publications

Administration's infrastructure initiative unveiled Energy Alert

Hogan Lovells Publications

Private funds key to Trump's infrastructure plans

Loading data